1. 72OAddition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers. (25th November 2018) Authors: Quintela-Fandino, M; Manso Sànchez, L M; Holgado Martín, E; Moreno, M C; Morales Murillo, S; Bermejo De Las Heras, B; Malon Gimenez, D; Colomer Bosch, R; Gonzalez Cortijo, L; Hornedo, J; Mouron, S; Muñoz, M; Escudero, S; Blanco, R; Mañes, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗